HIV-1 infection is characterized by an early peak of viremia
|
|
- Cassandra Warren
- 5 years ago
- Views:
Transcription
1 The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals Marylyn M. Addo*, Marcus Altfeld*, Eric S. Rosenberg*, Robert L. Eldridge*, Mary N. Philips*, Kathleen Habeeb*, Ashok Khatri, Christian Brander*, Gregory K. Robbins*, Gail P. Mazzara, Philip J. R. Goulder*, Bruce D. Walker*, and the HIV Controller Study Collaboration *Partners AIDS Research Center and Infectious Disease Division, Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114; and Therion Biologics Corporation, Cambridge, MA Edited by Robert C. Gallo, Institute of Human Virology, Baltimore, MD, and approved November 28, 2000 (received for review October 20, 2000) The HIV-1 regulatory proteins Rev and Tat are expressed early in the virus life cycle and thus may be important targets for the immune control of HIV-1-infection and for effective vaccines. However, the extent to which these proteins are targeted in natural HIV-1 infection as well as precise epitopes targeted by human cytotoxic T lymphocytes (CTL) remain to be defined. In the present study, 57 HIV-1-infected individuals were screened for responses against Tat and Rev by using overlapping peptides spanning the entire Tat and Rev proteins. CD8 T cell responses against Tat and Rev were found in up to 19 and 37% of HIV-1- infected individuals, respectively, indicating that these regulatory proteins are important targets for HIV-1-specific CTL. Despite the small size of these proteins, multiple CTL epitopes were identified in each. These data indicate that Tat and Rev are frequently targeted by CTL in natural HIV-1 infection and may be important targets for HIV vaccines. HIV-1 infection is characterized by an early peak of viremia that declines coincident with the development of strong cytotoxic T lymphocyte (CTL) responses (1 3) (reviewed in refs. 4 and 5). Selection for mutations within CTL epitopes demonstrates that CTL exert pressure on virus replication in vivo (6 10), and studies in macaques have provided compelling in vivo data for the role of CD8 T cells in controlling viremia in both acute and chronic simian immunodeficiency virus (SIV) infection (11, 12). HIV-1-infected individuals who are treated during acute infection show enhancement of both CTL and T helper cell responses against HIV-1 associated with subsequent viral control after treatment interruption (13). Induction of HIV-1-specific cytotoxic T cell responses is therefore considered an important goal for AIDS vaccines (14). Thus far, the analysis of HIV-1-specific CTL responses has been largely dominated by the study of structural HIV-1 proteins Gag, Pol, and Env, expressed later in the viral life cycle (15). The extent to which the earlier expressed regulatory proteins HIV-1 Tat and Rev are targeted in natural infection as well as precise CTL epitopes within these proteins remains to be defined. Responses directed against these early proteins may be particularly important in viral containment during AIDS-virus infection, because HIV-1 Tat and Rev are the dominant viral proteins produced before Nef down-regulates MHC class I molecules on the cell surface (16). To identify the determinants of natural and vaccine-induced immune responses directed against Tat and Rev, a detailed analysis of immune responses against these proteins in natural HIV-1 infection is warranted. This is of particular interest because no CTL epitope has yet been identified for HIV-1 Tat and only one for HIV-1 Rev (15, 17). We applied a comprehensive approach of screening for specific CD8 T cell responses by using overlapping peptides spanning the entire HIV-1 Tat and Rev sequences. This report describes the first CTL epitope within HIV-1 Tat and additional CTL epitopes within HIV-1 Rev and provides evidence that these proteins are frequent targets of cellular host defenses. Materials and Methods Subjects. Fifty-seven HIV-1-infected and 10 HIV-1-negative individuals were studied at the Massachusetts General Hospital (MGH). HIV-1-infected persons included 32 subjects who were diagnosed and treated with highly active antiretroviral therapy (HAART) within 180 days of HIV-1 seroconversion (18), 12 individuals with chronic treated HIV-1 infection, and 13 HIV- 1-infected individuals from the HIV-1 Controller Study Cohort, who contained their HIV-1 plasma viremia below 1,000 RNA copies per milliliter in the absence of antiretroviral therapy (referred to as controllers ) (summary is published as supplemental data on the PNAS web site, At the time of first CTL analysis, subjects on HAART had been treated for 6 12 months. HLA class I typing was performed at the MGH Tissue Typing Laboratory by using sequence-specific primer PCR (19). The study was approved by the MGH Institutional Review Board, and all individuals gave informed consent for participation in the studies. Generation of CTL Clones. Specific CTL lines were isolated by limiting dilution and maintained as described (20, 21). HIV-1- specific cytotoxicity was assessed by 51 chromium-release assay (22) by using autologous B-lymphoblastoid cell lines pulsed with peptides or infected with recombinant vaccinia virus (rvv) expressing either HIV-1 Tat or Rev (Therion Biologics, Cambridge, MA). HLA restriction of CTL epitopes was determined by using a panel of partially HLA-matched target cells (21). This paper was submitted directly (Track II) to the PNAS office. Abbreviations: CTL, cytotoxic T lymphocyte; SIV, simian immunodeficiency virus; rvv, recombinant vaccinia virus; SFC, spot-forming cells; PBMC, peripheral blood mononuclear cells. To whom reprint requests should be addressed at: MGH-East, th Street, Charlestown, MA bwalker@helix.mgh.harvard.edu. The HIV Controller Study Collaboration: Charles C. Carpenter, Brown University School of Medicine, Providence, RI 02903; Jon Fuller, Boston Medical Center, Boston, MA 02118; Geoffrey A. Modest, Upham s Corner Health Center, Dorchester, MA 02125; Jürgen K. Rockstroh, Medizinische Klinik der Friedrich Wilhelms-Universität, Bonn, Germany; Gerd Fätkenheuer, Bernd Salzberger, Alexander Jütte, Medizinische Klinik I der Universität zu Köln, Köln, Germany; and Spyros A. Kalams, Nesli Basgoz, Partners AIDS Research Center and ID Unit, Massachusetts General Hospital Harvard Medical School, Boston, MA The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C solely to indicate this fact. IMMUNOLOGY PNAS February 13, 2001 vol. 98 no
2 Table 1. Magnitude of peptide-specific CD8 responses directed against Tat overlapping peptides as measured by IFN- ELISPOT (SFC 10 6 PBMC) Subject HIV status TAT-1 TAT-4 TAT-6 TAT-7 TAT-8 Tat-10 Tat-11 Tat-15 ACTD Acute AC07 Acute AC41 Acute AC09 Acute Chronic Chronic O13572j Controller MSM 0105 Controller MJR 0515 Controller F BN Controller HC/BN Controller Synthetic HIV-1 Peptides. Peptides were synthesized on an automated peptide synthesizer (MBS 396, Advanced ChemTech) by using fluorenylmethoxycarbonyl chemistry. Twenty-one overlapping peptides spanning the HIV-1 BRU-B clade Rev sequence (14 16 mers with 10-aa overlap) and 15 overlapping peptides spanning the HIV-1 BRU-B clade Tat sequence (12 18 mers with 10-aa overlap) were generated (sequences listed in supplemental material). In addition, peptides corresponding to described optimal HIV-1 CTL epitopes and a panel of 259 overlapping peptides (15 20 mers) spanning the entire p17 Gag, p24 Gag, gp41 Env, gp120 Env, RT, and Nef sequence were used. ELISPOT Assay. HIV-1-specific CD8 T cell responses were quantified in duplicate by ELISPOT assay using fresh peripheral blood mononuclear cells (PBMC) ( ) and peptide (10 5 M), as described previously (23). IFN- -producing cells were counted by direct visualization and are expressed as spot-forming cells (SFC) per 10 6 PBMC. The number of specific IFN- -secreting T cells was calculated by subtracting the negative control value from the established SFC count. Negative controls were always 30 SFC per 10 6 input cells. CD8 T cell responses were also measured by using rvv-based IFN- ELISPOT assay as described elsewhere (24). Fine Mapping of CTL Epitopes. Fine mapping of the CD8 T cell response was achieved by ELISPOT assay by using serial dilutions of truncated peptides as described (23). The optimal peptide was defined as the peptide that induced specific IFN- production by T cells at the lowest peptide concentration. ELISPOT results were confirmed by using the same peptide truncations in fine-mapping assays by 51 chromium release assay, as described previously (21). All experiments were run in duplicate or triplicate. Flow-Cytometric Detection of Antigen-Induced Intracellular IFN-. Intracellular cytokine staining assays were performed as described elsewhere with minor modifications (25 27), by using PBMC or CTL lines and the following antibodies: anti-cd8-percp, anti-cd4-apc, and anti-ifn- -FITC. Cells were analyzed on a FACSCalibur flow cytometer (Becton Dickinson). Statistical Analysis. Statistical analysis was carried out by using GRAPHPAD PRISM Version 2.00 for Windows 95 (GraphPad, San Diego). Statistical significance (P values) of results was calculated by two-tailed t test and by 2 analysis. Results CD8 T Cell Responses Against HIV-1 Tat and Rev Peptides. Fiftyseven HIV-1-infected individuals were screened for CD8 T cell responses against the HIV-1 proteins Tat and Rev by using overlapping peptides in an IFN- ELISPOT assay. PBMC from (19.3%) HIV-1-positive study subjects recognized at least 1 overlapping Tat peptide (Table 1), and (37%) individuals had responses against 1 or more Rev peptides (Table 2). Magnitudes of responses against Tat peptides ranged from SFC 10 6 PBMC (median 250); frequencies for Rev responses showed a range from 40 to 900 SFC 10 6 PBMC (median 220). All responses were CD8 T cell mediated as determined by CD4 T cell depletion and or flow-based analysis of peptide-specific intracellular IFN- production by CD8 T cells (data not shown). The responses identified through screening with overlapping peptides correlated with the ELISPOT results by using rvv-expressing HIV-1 Tat and Rev in a subset of study subjects (data not shown). No responses against the Tat and Rev peptides were observed in the 10 HIV-1-negative individuals used as controls. For both Tat and Rev, multiple regions were targeted in functional as well as nonfunctional domains of the proteins. These included 8 of the 15 Tat peptides and 10 of 21 Rev peptides (Figs. 1 and 2). However, no single Tat peptide was recognized by more than 7%, and no single Rev peptide was targeted by more than 12% of infected persons. Frequency of Recognition of Tat and Rev. To address how frequently Tat and Rev were recognized compared with other HIV-1 proteins, we screened a subset of 36 individuals with a total of 259 overlapping peptides spanning the entire p17-gag, p24-gag, gp41-env, gp120-env, RT, and Nef sequence (Table 3). By dividing frequency of recognition by the number of amino acids per protein (and thus adjusting for protein length), both Rev and Tat were comparable to Nef and p24-gag in frequency of recognition and receive higher scores than RT, gp41-env, and gp120-env. Analysis of Differences Among Distinct Groups of HIV-1-Infected Individuals. We next evaluated the breadth and magnitude of CTL responses directed against Rev and Tat among three different subgroups of infected persons. CTL responses directed against both Tat and Rev were more frequently observed in persons controlling viremia without medications (controllers) (39 and 46%, respectively), compared with treated individuals with chronic (17 and 41%, respectively) or acute (13 and 31%, respectively) infection (Tables 1 and 2). However, these differences did not reach statistical significance. Controllers targeted more CTL epitopes within HIV-1 Tat, compared with the treated individuals (median of 2 epitopes compared with a median of 1 epitope, P 0.03), and responses directed against these epitopes were of significantly higher magnitude in controllers ( SFC 10 6 PBMC vs SFC 10 6 PBMC, P 0.01). In contrast, differences between the groups did not reach statistical significance for CTL responses directed against Rev. Functional Characteristics of HIV-1 Rev- and Tat-Specific CD8 T Cell Lines. The above data provide evidence that CD8 T cells are triggered to produce IFN- in response to Tat and Rev peptides but Addo et al.
3 Table 2. Magnitude of peptide-specific CD8 responses directed against Rev overlapping peptides as measured by IFN- ELISPOT (SFC 10 6 PBMC) Subject HIV status REV-1 REV-2 REV-3 REV-4 REV-6 REV-13 REV-14 REV-15 REV-16 REV-20 REV-21 AC04 Acute ACTD Acute AC13 Acute AC41 Acute AC35 Acute AC09 Acute AC42 Acute AC43 Acute AC39 Acute AC47 Acute Chronic Chronic Chronic Chronic AD Chronic j Controller TMH#3 Controller pg Controller F BN Controller HC BN Controller MAL Controller do not address their ability to recognize processed viral proteins or to lyse cells. Peptide-specific CD8 T cell lines for both Tat (peptides Tat-1, Tat-8, Tat-11) and Rev (peptides Rev-3, Rev-14) responses were therefore generated to further address the functional characteristics of these cells. CD8 T cell lines were first evaluated for their ability to produce IFN- on peptide stimulation and then tested for CTL activity in standard 51 Cr-release assays. Antigen-specific IFN- production and lysis of target cells presenting Tat (Fig. 3 a and b) and Rev (data not shown) peptides was readily evident. 51 Cr-release assays performed by using autologous B-lymphoblastoid cell line infected with rvv expressing Tat (Fig. 3) and Rev (data not shown) confirmed that these epitopes were effectively processed intracellularly. for the dormant responses the smallest truncated peptide that would afford maximal lysis at the lowest concentration. Fig. 4 a f summarizes the determination of HLA restriction and the fine mapping of the optimal epitopes. The response to the Tat-1 peptide was found to be restricted by HLA-B53 (Fig. 4a), one of the most frequent HLA class I alleles in the black population worldwide (28). The optimal epitope was identified as EPVD- PRLEPW (position Tat 2 11) by both 51 Cr-release assay (Fig. 4b) and ELISPOT (data not shown) and exactly fits the published peptide-binding motif for HLA-B53 (29). Of the 4 persons who recognized peptide Tat-1, only 2 expressed HLA-B53 and recognized the Tat epitope restricted by this allele, suggesting that IMMUNOLOGY Identification of Optimal CTL Epitopes Within HIV-1 Tat and Rev. Despite over 130 optimal HIV-1-specific CTL epitopes now defined (15), no Tat epitopes have been mapped, and only one Rev epitope has been reported (17). We therefore determined Fig. 1. Number of study subjects (dark columns) with specific CD8 responses against the individual overlapping Tat peptides (1 15) as measured by ELIS- POT. The clear horizontal bar indicates the HIV-1 Tat protein domains corresponding to the overlapping peptides. A, acidic amino terminal; Cy-rich, cysteine-rich region; C, core domain; Q-rich, glutamine-rich domain; a total of 57 subjects were evaluated. Fig. 2. Number of study subjects (dark columns) with specific CD8 responses against the individual overlapping Rev peptides (1 21) as measured by ELISPOT. The clear horizontal bar indicates the regions of the HIV-1 Rev protein corresponding to the overlapping peptides. M, multimerization regions; nls, nuclear localization signal; rre, rev responsive element binding; nes, nuclear export signal. A total of 57 subjects were evaluated. Addo et al. PNAS February 13, 2001 vol. 98 no
4 Table 3. Percentage of subjects with CTL responses against specific HIV-1 proteins in a subset of 36 individuals who were screened for HIV-1-specific CD8 responses by using overlapping peptides spanning Tat, Rev, Nef, RT, p17-gag, p24-gag, gp41-env, gp120-env by INF- ELISPOT Group n TAT, % REV, % NEF, % RT, % p17, % p24, % gp41, % gp120, % Acute Chronic Controller Total No. amino acids Amino acid adjusted score* *Frequency of recognition in percent divided by number of amino acids per protein. other restricting alleles and possibly other optimal epitopes might be contained within Tat-1. The CD8 T cell response to the Rev-3 peptide was HLA- B*5801-restricted (Fig. 4c) with KAVRIKLFLY as the optimal epitope (Fig. 4d). It was also recognized by another individual in whom it was restricted by HLA*B5701 (data not shown), an HLA class I allele closely related to HLA-B*5801, suggesting crosspresentation between these two HLA alleles, which has been described previously (30). The most frequently recognized response among all subjects was found to Rev-peptides 13 and 14. HLA restriction identified HLA-Cw5 as the restricting element (Fig. 4e), for which no optimal HIV-specific CTL epitope has been reported thus far (15). Fine mapping revealed the peptide SAEPVPLQL (Rev-SL9 at position Rev 69 77) as the optimal CTL epitope (Fig. 4f). All study individuals expressing HLA-Cw5 were subsequently tested for responses against Rev-SL9 (Table 4). Five of 11 (45%) individuals recognized the epitope at magnitudes ranging from 120 to 730 (median 440) SFC 10 6 PBMC. Of interest, the epitope was also recognized by 2 5 individuals (AC39, AC43) expressing HLA-Cw8, an HLA molecule differing by only 4 amino acids from HLA-Cw5 (see http: HIG ), suggesting promiscuous presentation of SAEPVPLQL between those HLA molecules. This epitope has also been reported as an HLA-B14-restricted CTL epitope; however, HLA-Cw types were not given for the individuals reported in that earlier study (17). Longitudinal Analysis of the Rev-SL9 Response. To also address the question of longitudinal persistence of responses over time and effects of antiviral therapy, the Rev-SL9 response was chosen because of its high frequency of recognition among the study subjects. Longitudinal samples were available for 6 Rev-SL9 responders, who were treated during acute HIV-1 infection and were analyzed 2 and 12 months after initiation of highly active antiretroviral therapy by using both ELISPOT and flow-based intracellular cytokine staining (ICS). Magnitudes of CTL responses as measured by ICS corresponded well to magnitudes determined by ELISPOT (data not shown). In all individuals, the response was present at both time points without significant changes in magnitude [ICS: 0.18% (range 0.1% 1%) vs. 0.2% (0.1% 0.8%) P 0.7; ELISPOT: 120 vs. 140SFC]. Two of these individuals (AC04 and AC13) underwent treatment interruption after 12 and 14 months of therapy (13). In both subjects, the response was augmented to higher levels on transient reexposure to antigen during treatment (see supplemental material), as previously demonstrated for CTL responses against structural proteins of HIV-1 (13). Discussion Very little detailed data are available on HIV-1-specific responses against the regulatory proteins Tat and Rev in humans (31). We therefore characterized CTL responses directed against HIV-1 Tat and Rev in 57 HIV-1-infected individuals comprehensively by using overlapping peptides spanning the entire Tat and Rev sequence of HIV-1. We observed that CTL responses to epitopes in Tat and Rev, characterized by both IFN- production and lysis of target cells, are frequently detectable in HIV-1-infected humans and may contribute importantly to the CD8 T cell response against HIV-1. Furthermore, to our knowledge this report includes the description of the first optimal CTL epitope within HIV-1 Tat and describes two Fig. 3. Functional characteristics exemplified for a Tat-1-specific CD8 T cell line. (a) Evaluation of ability to produce IFN- by flow-based intracellular cytokine staining. (b) Cytotoxic activity for the T cell line as measured by standard 51 Cr-release assay at effector-to-target ratios 20:1 and 10:1. Targets included peptide-pulsed autologous B-lymphoblastoid cell line (LCL) and autologous B-LCL infected with rvv expressing Tat rvvtat. Control conditions were established by using unpulsed or rvvlac infected autologous B-cell lines (20) Addo et al.
5 IMMUNOLOGY Fig. 4. Characterization of three CTL epitopes within HIV-1 Tat and Rev. The responses were further investigated in study subjects 6007 (HLA A*3002 -, B53 *5801, Cw4 7) (a d) and AC04 (HLA A2 11, B18 44, Cw5 Cw12)(e and f). HLA restriction was performed by using peptides presented by autologous and partially HLA-mismatched L-BCL in a 51 Cr-release assay (a, c, and e). Fine mapping of the optimal epitope was done by using serial dilutions of truncated peptides in cytotoxicity assays (b, d, and f). Effector-to-target ratio for all assays was 20:1. additional novel CTL epitopes within HIV-1 Rev, one of which represents the first HLA-Cw5-restricted HIV CTL epitope. These results thus indicate that these proteins expressed early in the viral life cycle are important targets for the cellular immune response, and that accurate dissection of CTL responses in natural infection needs to incorporate analysis of Tat and Rev. CTL responses against regulatory proteins such as Tat and Rev may be of major immunologic importance because of their early expression in the viral life cycle (32) before Nef downregulates MHC class I molecules on the cell surface (16). The pattern of responses observed by screening with peptides suggests that particular regions of the proteins are preferentially targeted. Most identified responses map to important functional domains of Tat and Rev. It has been suggested that CTL responses directed against functionally important regions within the virus could be more effective, as CTL-induced viral escape mutations within these domains are less likely to occur or may lead to reduced viral competence (33). Longitudinal analysis will have to evaluate whether the virus is less likely to escape from CTL that target epitopes located in these regions of Rev and Tat. The potential importance of Tat-specific CTL has been suggested in an SIV model of AIDS virus infection showing that Tat-specific CTL select for virus escape variants very early in primary SIV infection (34). The potential for immunization with Tat and Rev immunogens has been addressed in both animal and human studies, with encouraging results. Studies in macaques by Table 4. HLA types and CD8 T cell-mediated responses to SAEPVPLQL (HIV-1-Rev) in study subjects expressing HLA-Cw5 and -Cw8 Subjects HLA type SFC 10 6 PBMC AC04 A2, 11 B18, 44 Cw5, AC35 A2, 74 B18, 72 Cw2, AC41 A2, 11 B35, 44 Cw4, AC13 A2, 68 B14, 44 Cw5, PG A2, 30 B44, 51 Cw2, AC39 A32, 68 B60, 64 Cw3, AC43 A24, 31 B14, 57 Cw7, Addo et al. PNAS February 13, 2001 vol. 98 no
6 using biologically active Tat protein (35), Tat toxoid (36), or recombinant vaccinia vectors expressing Tat and Rev proteins (37) as immunogens showed attenuation of virus replication and disease. Clinical studies in humans assessing safety and immunogenicity of HIV-1 Tat toxoid (38) and an HIV-1 Revcontaining DNA vaccine have been performed. The use of overlapping peptides in the ELISPOT assays indicates that there are multiple epitopes in Tat and Rev, three of which are optimally defined. Only one of these epitopes (Rev-SAEPVPLQL) had been previously described, albeit as an HLA-B14-restricted CTL epitope (17). However, the HLA-Cw locus was not investigated in the earlier study. In the present study, the response was shown to be HLA-Cw5-restricted and thus represents the first HIV-specific CTL epitope restricted by this HLA class I molecule. The epitope was recognized by several additional individuals expressing HLA-Cw5, as well as 2 individuals expressing HLA-Cw8, but not Cw5. Because the amino acid sequences of HLA-Cw5 and -Cw8 differ only in four amino acid positions, this finding is suggestive of promiscuous presentation between these two restriction elements, as already described for epitopes restricted by HLA-A and -B alleles (23, 30, 39). Our findings indicate that the HLA-C locus is an important component to consider in the determination of HLA restriction, especially in view of linkage disequilibrium between certain HLA-B and -C alleles. In conclusion, these data indicate that the regulatory proteins HIV-1 Tat and Rev are frequent targets for CTL in natural HIV-1 infection. The identification of epitopes within these proteins should facilitate the testing of CTL responses induced by vaccines expressing Tat and or Rev and will be important to investigate in studies of HIV pathogenesis. These findings should also encourage investigation of responses to other regulatory proteins such as Vif, Vpr, and Vpu, which may also serve as targets for CTL responses. The epitopes defined herein will allow for a more detailed analysis of CTL responses directed against regulatory proteins and may potentially represent candidates for future multicomponent HIV vaccines. We thank all study participants. This work was supported by grants to M.M.A. from the Deutsche Forschungsgemeinschaft (AD ), to M.A. from the Deutscher Akademischer Austauschdienst (Grant D ), to E.S.R. from the Doris Duke Charitable Foundation and the National Institutes of Health (NIH), to P.J.R.G. from the Elizabeth Glaser Pediatric AIDS Foundation, the United Kingdom Medical Research Foundation (Grant G ), and the NIH (AI46995), and to B.D.W. through the NIH (AI28568, AI30914) and the Doris Duke Charitable Foundation. P.J.R.G. is an Elizabeth Glaser Scientist of the Elizabeth Glaser Pediatric AIDS Foundation. B.D.W. is a Doris Duke Distinguished Clinical Science Professor. 1. Borrow, P., Lewicki, H., Hahn, B. H., Shaw, G. M. & Oldstone, M. B. (1994) J. Virol. 68, Koup, R. A., Safrit, J. T., Cao, Y., Andrews, C. A., McLeod, G., Borkowsky, W., Farthing, C. & Ho, D. D. (1994) J. Virol. 68, Yasutomi, Y., Reimann, K. A., Lord, C. I., Miller, M. D. & Letvin, N. L. (1993) J. Virol. 67, Brander, C. & Walker, B. D. (1999) Curr. Opin. Immunol. 11, Goulder, P. J., Rowland-Jones, S. L., McMichael, A. J. & Walker, B. D. (1999) AIDS 13, S121 S Evans, D. T., O Connor, D. H., Jing, P., Dzuris, J. L., Sidney, J., da Silva, J., Allen, T. M., Horton, H., Venham, J. E., Rudersdorf, R. A., et al. (1999) Nat. Med. 5, Borrow, P., Lewicki, H., Wei, X., Horwitz, M. S., Peffer, N., Meyers, H., Nelson, J. A., Gairin, J. E., Hahn, B. H., Oldstone, M. B. & Shaw, G. M. (1997) Nat. Med. 3, Koenig, S., Conley, A. J., Brewah, Y. A., Jones, G. M., Leath, S., Boots, L. J., Davey, V., Pantaleo, G., Demarest, J. F., Carter, C., et al. (1995) Nat. Med. 1, Price, D. A., Goulder, P. J., Klenerman, P., Sewell, A. K., Easterbrook, P. J., Troop, M., Bangham, C. R. & Phillips, R. E. (1997) Proc. Natl. Acad. Sci. USA 94, Goulder, P. J., Phillips, R. E., Colbert, R. A., McAdam, S., Ogg, G., Nowak, M. A., Giangrande, P., Luzzi, G., Morgan, B., Edwards, A., et al. (1997) Nat. Med. 3, Schmitz, J. E., Kuroda, M. J., Santra, S., Sasseville, V. G., Simon, M. A., Lifton, M. A., Racz, P., Tenner-Racz, K., Dalesandro, M., Scallon, B. J., et al. (1999) Science 283, Jin, X., Bauer, D. E., Tuttleton, S. E., Lewin, S., Gettie, A., Blanchard, J., Irwin, C. E., Safrit, J. T., Mittler, J., Weinberger, L., et al. (1999) J. Exp. Med. 189, Rosenberg, E. S., Altfeld, M., Poon, S. H., Phillips, M. N., Wilkes, B. M., Eldridge, R. L., Robbins, G. K., D Aquila, R. T., Goulder, P. J. & Walker, B. D. (2000) Nature (London) 407, Letvin, N. L. (1998) J. Clin. Invest. 102, Brander, C. and Goulder, P. J. R. (1999) in HIV Molecular Immunology Database 1999, eds. Korber, B. T. M., Brander, C., Walker, B. D., Koup, R. A., Moore, J., Haynes, B. & Meyers, G. (Los Alamos Natl. Lab., Los Alamos, NM). 16. Collins, K. L., Chen, B. K., Kalams, S. A., Walker, B. D. & Baltimore, D. (1998) Nature (London) 391, Van Baalen, C. A., Schutten, M., Huisman, R. C., Boers, P. H., Gruters, R. A. & Osterhaus, A. D. (1998) J. Virol. 72, Janssen, R. S., Satten, G. A., Stramer, S. L., Rawal, B. D., O Brien, T. R., Weiblen, B. J., Hecht, F. M., Jack, N., Cleghorn, F. R., Kahn, J. O., et al. (1998) J. Am. Med. Soc. 280, Bunce, M., Fanning, G. C. & Welsh, K. I. (1995) Tissue Antigens 45, Johnson, R. P., Trocha, A., Yang, L., Mazzara, G. P., Panicali, D. L., Buchanan, T. M. & Walker, B. D. (1991) J. Immunol. 147, Walker, B. D., Flexner, C., Birch-Limberger, K., Fisher, L., Paradis, T. J., Aldovini, A., Young, R., Moss, B. & Schooley, R. T. (1989) Proc. Natl. Acad. Sci. USA 86, Walker, B. D., Chakrabarti, S., Moss, B., Paradis, T. J., Flynn, T., Durno, A. G., Blumberg, R. S., Kaplan, J. C., Hirsch, M. S. & Schooley, R. T. (1987) Nature (London) 328, Altfeld, M. A., Trocha, A., Eldridge, R. L., Rosenberg, E. S., Phillips, M. N., Addo, M. M., Sekaly, R. P., Kalams, S. A., Burchett, S. A., McIntosh, K., et al. (2000) J. Virol. 74, Larsson, M., Jin, X., Ramratnam, B., Ogg, G. S., Engelmayer, J., Demoitie, M. A., McMichael, A. J., Cox, W. I., Steinman, R. M., Nixon, D. & Bhardwaj, N. (1999) AIDS 13, Pitcher, C. J., Quittner, C., Peterson, D. M., Connors, M., Koup, R. A., Maino, V. C. & Picker, L. J. (1999) Nat. Med. 5, Betts, M. R., Casazza, J. P., Patterson, B. A., Waldrop, S., Trigona, W., Fu, T. M., Kern, F., Picker, L. J. & Koup, R. A. (2000) J. Virol. 74, Goulder, P. J. R., Tang, Y., Brander, C., Betts, M., Trocha, A., He, S., Rosenberg, E. S., Ogg, G., O Callaghan, C. A., Kalams, S. A., et al. (2000) J. Exp. Med. 192, Sidney, J., Grey, H. M., Kubo, R. T. & Sette, A. (1996) Immunol. Today 17, Smith, K. J., Reid, S. W., Harlos, K., McMichael, A. J., Stuart, D. I., Bell, J. I. & Jones, E. Y. (1996) Immunity 4, Goulder, P. J. R., Bunce, M., Krausa, P., McIntyre, K., Crowley, S., Morgan, B., Edwards, A., Giangrande, P., Phillips, R. E. & McMichael, A. J. (1996) AIDS Res. Hum. Retroviruses 12, van Baalen, C. A., Pontesilli, O., Huisman, R. C., Geretti, A. M., Klein, M. R., de Wolf, F., Miedema, F., Gruters, R. A. & Osterhaus, A. D. (1997) J. Gen. Virol. 78, Cullen, B. R. (1991) FASEB J. 5, Nietfield, W., Bauer, M., Fevrier, M., Maier, R., Holzwarth, B., Frank, R., Maier, B., Riviere, Y. & Meyerhans, A. (1995) J. Immunol. 154, Allen, T. M., O Connor, D. H., Jing, P., Dzuris, J. L., Mothe, B. R., Vogel, T. U., Dunphy, E., Liebl, M. E., Emerson, C., Wilson, N., et al. (2000) Nature (London) 407, Cafaro, A., Caputo, A., Fracasso, C., Maggiorella, M. T., Goletti, D., Baroncelli, S., Pace, M., Sernicola, L., Koanga-Mogtomo, M. L., Betti, M., et al. (1999) Nat. Med. 5, Pauza, C. D., Trivedi, P., Wallace, M., Ruckwardt, T. J., Le Buanec, H., Lu, W., Bizzini, B., Burny, A., Zagury, D. & Gallo, R. C. (2000) Proc. Natl. Acad. Sci. USA 97, (First Published March 21, 2000; pnas ) 37. Osterhaus, A. D., van Baalen, C. A., Gruters, R. A., Schutten, M., Siebelink, C. H., Hulskotte, E. G., Tijhaar, E. J., Randall, R. E., van Amerongen, G., Fleuchaus, A., et al. (1999) Vaccine 17, Gringeri, A., Santagostino, E., Muca-Perja, M., Le Buanec, H., Bizzini, B., Lachgar, A., Zagury, J. F., Rappaport, J., Burny, A., Gallo, R. C. & Zagury, D. (1999) J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 20, Threlkeld, S. C., Wentworth, P. A., Kalams, S. A., Wilkes, B. M., Ruhl, D. J., Keogh, E., Sidney, J., Southwood, S., Walker, B. D. & Sette, A. (1997) J. Immunol. 159, Addo et al.
Expansion of pre-existing, lymph node-localized CD8 + T cells during supervised treatment interruptions in chronic HIV-1 infection
Expansion of pre-existing, lymph node-localized CD8 + T cells during supervised treatment interruptions in chronic HIV-1 infection Marcus Altfeld, 1 Jan van Lunzen, 2 Nicole Frahm, 1,2 Xu G. Yu, 1 Claus
More informationRapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers
Rapid perforin upregulation directly ex vivo by CD8 + T cells is a defining characteristic of HIV elite controllers Adam R. Hersperger Department of Microbiology University of Pennsylvania Evidence for
More informationAND BRUCE D. WALKER 1
JOURNAL OF VIROLOGY, Feb 2001, p. 1339 1347 Vol. 75, No. 3 0022-538X/01/$04.00 0 DOI: 10.1128/JVI.75.3.1339 1347.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Rapid Definition
More informationHow HIV Causes Disease Prof. Bruce D. Walker
How HIV Causes Disease Howard Hughes Medical Institute Massachusetts General Hospital Harvard Medical School 1 The global AIDS crisis 60 million infections 20 million deaths 2 3 The screen versions of
More informationDEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED
DEBATE ON HIV ENVELOPE AS A T CELL IMMUNOGEN HAS BEEN GAG-GED Viv Peut Kent Laboratory, University of Melbourne, Australia WHY ENVELOPE? Env subject to both humoral and cellular immune responses Perhaps
More informationAnalysis of Total Human Immunodeficiency Virus (HIV)-Specific CD4 and CD8 T-Cell Responses: Relationship to Viral Load in Untreated HIV Infection
JOURNAL OF VIROLOGY, Dec. 2001, p. 11983 11991 Vol. 75, No. 24 0022-538X/01/$04.00 0 DOI: 10.1128/JVI.75.24.11983 11991.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Analysis
More informationReceived 1 August 2000/Accepted 30 October 2000
JOURNAL OF VIROLOGY, Feb. 2001, p. 1301 1311 Vol. 75, No. 3 0022-538X/01/$04.00 0 DOI: 10.1128/JVI.75.3.1301 1311.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Identification
More informationFunctionally Inert HIV-specific Cytotoxic T Lymphocytes Do Not Play a Major Role in Chronically Infected Adults and Children
Functionally Inert HIV-specific Cytotoxic T Lymphocytes Do Not Play a Major Role in Chronically Infected Adults and Children By Philip J.R. Goulder,* Yanhua Tang,* Christian Brander,* Michael R. Betts,
More informationOn an individual level. Time since infection. NEJM, April HIV-1 evolution in response to immune selection pressures
HIV-1 evolution in response to immune selection pressures BISC 441 guest lecture Zabrina Brumme, Ph.D. Assistant Professor, Faculty of Health Sciences Simon Fraser University http://www3.niaid.nih.gov/topics/hivaids/understanding/biology/structure.htm
More informationEmergence of cytotoxic T lymphocyte escape mutations in nonpathogenic simian immunodeficiency virus infection
Eur. J. Immunol. 2001. 31: 3207 3217 CTL escape in nonpathogenic SIV infection 3207 Emergence of cytotoxic T lymphocyte escape mutations in nonpathogenic simian immunodeficiency virus infection Amitinder
More informationFully Differentiated HIV-1 Specific CD8+ T Effector Cells are More Frequently Detectable in Controlled than in Progressive HIV-1 Infection
Fully Differentiated HIV-1 Specific CD8+ T Effector Cells are More Frequently Detectable in Controlled than in Progressive HIV-1 Infection The Harvard community has made this article openly available.
More informationNK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections
NK mediated Antibody Dependent Cellular Cytotoxicity in HIV infections Amy Chung Dr. Ivan Stratov Prof. Stephen Kent ADCC process consists of Target cell QuickTime and a TIFF (Uncompressed) FcγR decompressor
More informationInnate and Cellular Immunology Control of Infection by Cell-mediated Immunity
Innate & adaptive Immunity Innate and Cellular Immunology Control of Infection by Cell-mediated Immunity Helen Horton PhD Seattle Biomedical Research Institute Depts of Global Health & Medicine, UW Cellular
More informationReceived 9 January 2003/Accepted 11 March 2003
JOURNAL OF VIROLOGY, July 2003, p. 7492 7501 Vol. 77, No. 13 0022-538X/03/$08.00 0 DOI: 10.1128/JVI.77.13.7492 7501.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Comprehensive
More informationRAISON D ETRE OF THE IMMUNE SYSTEM:
RAISON D ETRE OF THE IMMUNE SYSTEM: To Distinguish Self from Non-Self Thereby Protecting Us From Our Hostile Environment. Innate Immunity Acquired Immunity Innate immunity: (Antigen nonspecific) defense
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY INFORMATION Association of HLA-DRB1-restricted CD4 + T cell responses with HIV immune control Srinika Ranasinghe 1, Sam Cutler 1, Isaiah Davis 1, Richard Lu 2, Damien Z. Soghoian 1, Ying
More informationComparison of the efficacy of early versus late viral proteins in vaccination against SIV
Vaccine 20 (2002) 2921 2927 Comparison of the efficacy of early versus late viral proteins in vaccination against SIV Koert J. Stittelaar a, Rob A. Gruters a,b, Martin Schutten a, Carel A. van Baalen a,
More informationPotential cross reactions between HIV 1 specific T cells and the microbiome. Andrew McMichael Suzanne Campion
Potential cross reactions between HIV 1 specific T cells and the microbiome Andrew McMichael Suzanne Campion Role of the Microbiome? T cell (and B cell) immune responses to HIV and Vaccines are influenced
More informationEmergence and Kinetics of Simian Immunodeficiency Virus-Specific CD8 T Cells in the Intestines of Macaques during Primary Infection
JOURNAL OF VIROLOGY, Nov. 2001, p. 10515 10519 Vol. 75, No. 21 0022-538X/01/$04.00 0 DOI: 10.1128/JVI.75.21.10515 10519.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Emergence
More informationReceived 14 July 2005/Accepted 3 September 2005
JOURNAL OF VIROLOGY, Dec. 2005, p. 14986 14991 Vol. 79, No. 23 0022-538X/05/$08.00 0 doi:10.1128/jvi.79.23.14986 14991.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved. Tat 28-35
More informationJVI Accepts, published online ahead of print on 7 March 2007 J. Virol. doi: /jvi
JVI Accepts, published online ahead of print on 7 March 2007 J. Virol. doi:10.1128/jvi.02763-06 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationReceived 15 August 1996/Accepted 8 November 1996
JOURNAL OF VIROLOGY, Feb. 1997, p. 1256 1264 Vol. 71, No. 2 0022-538X/97/$04.00 0 Copyright 1997, American Society for Microbiology Overlapping Epitopes in Human Immunodeficiency Virus Type 1 gp120 Presented
More informationCD8 memory, immunodominance, and antigenic escape
2704 D. Wodarz and M. A. Nowak Eur. J. Immunol. 2000. 30: 2704 2712 CD8 memory, immunodominance, and antigenic escape Dominik Wodarz and Martin A. Nowak 1 Institute for Advanced Study, Princeton, USA Previous
More informationRAISON D ETRE OF THE IMMUNE SYSTEM:
RAISON D ETRE OF THE IMMUNE SYSTEM: To Distinguish Self from Non-Self Thereby Protecting Us From Our Hostile Environment. Innate Immunity Adaptive Immunity Innate immunity: (Antigen - nonspecific) defense
More informationFayth K. Yoshimura, Ph.D. September 7, of 7 HIV - BASIC PROPERTIES
1 of 7 I. Viral Origin. A. Retrovirus - animal lentiviruses. HIV - BASIC PROPERTIES 1. HIV is a member of the Retrovirus family and more specifically it is a member of the Lentivirus genus of this family.
More informationHIV Anti-HIV Neutralizing Antibodies
,**/ The Japanese Society for AIDS Research The Journal of AIDS Research : HIV HIV Anti-HIV Neutralizing Antibodies * Junji SHIBATA and Shuzo MATSUSHITA * Division of Clinical Retrovirology and Infectious
More informationMechanisms of antagonism of HIVspecific CD4+ T cell responses BSRI
Mechanisms of antagonism of HIVspecific CD4+ T cell responses BSRI Problems Virus escape from immune recognition Antagonism of T cell responses Peptide-MHC-TCR interaction T cell antagonism Variants of
More informationMaterials and Methods
1133 Decline of Simian Immunodeficiency Virus (SIV) Specific Cytotoxic T Lymphocytes in the Peripheral Blood of Long-Term Nonprogressing Macaques Infected with SIVmac32H-J5 Anna-Maria Geretti, 1,a Ellen
More informationSuperior Control of HIV-1 Replication by CD8+ T Cells Targeting Conserved Epitopes: Implications for HIV Vaccine Design
Superior Control of HIV-1 Replication by CD8+ T Cells Targeting Conserved Epitopes: Implications for HIV Vaccine Design Pratima Kunwar 1,7, Natalie Hawkins 2, Warren L. Dinges 1,3, Yi Liu 5, Erin E. Gabriel
More informationAre we targeting the right HIV determinants?
QuickTime et un décompresseur TIFF (non compressé) sont requis pour visionner cette image. AIDS Vaccine 2009 October 22 nd 2009 - Paris Are we targeting the right HIV determinants? Françoise BARRÉ-SINOUSSI
More informationReceived 25 April 2002/Accepted 21 May 2002
JOURNAL OF VIROLOGY, Sept. 2002, p. 8757 8768 Vol. 76, No. 17 0022-538X/02/$04.00 0 DOI: 10.1128/JVI.76.17.8757 8768.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved. Clustering
More informationA DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques
Journal of General Virology (2002), 83, 75 80. Printed in Great Britain... SHORT COMMUNICATION A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses
More informationAntiviral therapy for HIV-infected patients has greatly improved
Specific therapy regimes could lead to long-term immunological control of HIV Dominik Wodarz* and Martin A. Nowak Institute for Advanced Study, Olden Lane, Princeton, NJ 08540 Communicated by Phillip A.
More informationInefficient Cytotoxic T Lymphocyte Mediated Killing of HIV-1 Infected Cells In Vivo
Inefficient Cytotoxic T Lymphocyte Mediated Killing of HIV-1 Infected Cells In Vivo The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters
More informationWhy are validated immunogenicity assays important for HIV vaccine development?
Why are validated immunogenicity assays important for HIV vaccine development? There is a need to compare immunogenicity of products in the pipeline, when similar or different in class when developed by
More informationSupporting Information
Supporting Information Sui et al..7/pnas.997 Pre-CLP CM9 LA9 SL Tat# Pol Vif % Tetramer + CD + CD + Vac+IL- +IL- Vac Fig. S. Frequencies of six different CD + CD + Mamu-A*-tetramer + cells were measured
More informationHIV acute infections and elite controllers- what can we learn?
HIV acute infections and elite controllers- what can we learn? Thumbi Ndung u, BVM, PhD KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH) and HIV Pathogenesis Programme (HPP), Doris Duke
More informationReceived 17 November 2003/Accepted 2 February 2004
JOURNAL OF VIROLOGY, July 2004, p. 7069 7078 Vol. 78, No. 13 0022-538X/04/$08.00 0 DOI: 10.1128/JVI.78.13.7069 7078.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved. Selection,
More informationClinical and experimental observations strongly suggest
Broadly Increased Sensitivity to Cytotoxic T Lymphocytes Resulting from Nef Epitope Escape Mutations 1 Ayub Ali,* Satish Pillai, Hwee Ng,* Rachel Lubong,* Douglas D. Richman, Beth D. Jamieson,* Yan Ding,
More informationComparison of Human Immunodeficiency Virus Antigens as Stimulants for Lymphocyte Proliferation Assays
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, May 2002, p. 525 529 Vol. 9, No. 3 1071-412X/02/$04.00 0 DOI: 10.1128/CDLI.9.3.525 529.2002 Copyright 2002, American Society for Microbiology. All Rights
More informationThe functional CD8 T cell response to HIV becomes type-specific in progressive disease
The functional CD8 T cell response to HIV becomes type-specific in progressive disease Sang Kyung Lee, Zhan Xu, Judy Lieberman, and Premlata Shankar Center for Blood Research and Department of Pediatrics,
More informationTreatment with IL-7 Prevents the Decline of Circulating CD4 + T Cells during the Acute Phase of SIV Infection in Rhesus Macaques
SUPPORTING INFORMATION FOR: Treatment with IL-7 Prevents the Decline of Circulating CD4 + T Cells during the Acute Phase of SIV Infection in Rhesus Macaques Lia Vassena, 1,2 Huiyi Miao, 1 Raffaello Cimbro,
More informationHuman Immunodeficiency Virus
Human Immunodeficiency Virus Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Viruses and hosts Lentivirus from Latin lentis (slow), for slow progression of disease
More informationAnti-SIV Cytolytic Molecules in Pigtail Macaques
AIDS RESEARCH AND HUMAN RETROVIRUSES Volume 24, Number 8, 2008 Mary Ann Liebert, Inc. DOI: 10.1089/aid.2008.0081 Anti-SIV Cytolytic Molecules in Pigtail Macaques Erik Rollman, Stephen J. Turner, Katherine
More informationReceived 19 September 2007/Accepted 21 November 2007
JOURNAL OF VIROLOGY, Feb. 2008, p. 1723 1738 Vol. 82, No. 4 0022-538X/08/$08.00 0 doi:10.1128/jvi.02084-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. Patterns of CD8 Immunodominance
More informationMutational Escape in HIV-1 CTL Epitopes Leads to Increased Binding to Inhibitory Myelomonocytic MHC Class I Receptors
Mutational Escape in HIV-1 CTL Epitopes Leads to Increased Binding to Inhibitory Myelomonocytic MHC Class I Receptors The MIT Faculty has made this article openly available. Please share how this access
More informationActivation of NK Cells by ADCC Antibodies and HIV Disease Progression
RAPID COMMUNICATION Activation of NK Cells by ADCC Antibodies and HIV Disease Progression Amy W. Chung, BSc, PhD,* Marjon Navis, PhD,* Gamze Isitman, BSc,* Leia Wren, BSc,* Julie Silvers, RN, Janaki Amin,
More informationRecombinant Vaccinia Virus-Induced T-Cell Immunity: Quantitation of the Response to the Virus Vector and the Foreign Epitope
JOURNAL OF VIROLOGY, Apr. 2002, p. 3329 3337 Vol. 76, No. 7 0022-538X/02/$04.00 0 DOI: 10.1128/JVI.76.7.3329 3337.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved. Recombinant
More informationHIV-1 Dual Infection and Neurocognitive Impairment
HIV-1 Dual Infection and Neurocognitive Impairment Gabriel Wagner, MD Assistant Professor of Medicine Infectious Diseases & Global Public Health UC San Diego HIV-Associated End Organ Damage Antiretroviral
More informationNIH Public Access Author Manuscript Nat Med. Author manuscript; available in PMC 2010 September 1.
NIH Public Access Author Manuscript Published in final edited form as: Nat Med. 2010 March ; 16(3): 319 323. doi:10.1038/nm.2089. Mosaic HIV-1 Vaccines Expand the Breadth and Depth of Cellular Immune Responses
More informationHuman Immunodeficiency Virus Type 1 (HIV-1)-Specific CD8 -T-Cell Responses for Groups of HIV-1-Infected Individuals with Different HLA-B*35 Genotypes
JOURNAL OF VIROLOGY, Dec. 2002, p. 12603 12610 Vol. 76, No. 24 0022-538X/02/$04.00 0 DOI: 10.1128/JVI.76.24.12603 12610.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved. Human
More informationControl of Human Immunodeficiency Virus Type 1 Is Associated with HLA-B*13 and Targeting of Multiple Gag-Specific CD8 T-Cell Epitopes
JOURNAL OF VIROLOGY, Apr. 2007, p. 3667 3672 Vol. 81, No. 7 0022-538X/07/$08.00 0 doi:10.1128/jvi.02689-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Control of Human Immunodeficiency
More informationTherapeutic strategies for immune reconstitution in acquired immunodeficiency syndrome
30 1, 1, 2, 3 1. ( ), 201508; 2., 200040; 3., 200032 : ( AIDS) ( HIV) 20 90,,,,,, AIDS, CD4 + T ( CTL), HIV, : ; ; Therapeutic strategies for immune reconstitution in acquired immunodeficiency syndrome
More informationEquine infectious anaemia virus proteins with epitopes most frequently recognized by cytotoxic T lymphocytes from infected horses
Journal of General Virology (2000), 81, 2735 2739. Printed in Great Britain... SHORT COMMUNICATION Equine infectious anaemia virus proteins with epitopes most frequently recognized by cytotoxic T lymphocytes
More informationMina John Institute for Immunology and Infectious Diseases Royal Perth Hospital & Murdoch University Perth, Australia
Mina John Institute for Immunology and Infectious Diseases Royal Perth Hospital & Murdoch University Perth, Australia AIDSvaccine conference, 14 th September 2011 IMGT HLA database July 2011 >5000 class
More informationAbstract. Introduction
Lack of Strong Immune Selection Pressure by the Immunodominant, HLA-A*0201 restricted Cytotoxic T Lymphocyte Response in Chronic Human Immunodeficiency Virus 1 Infection Christian Brander,* Kelly E. Hartman,*
More informationMagnitude and Diversity of Cytotoxic-T-Lymphocyte Responses Elicited by Multiepitope DNA Vaccination in Rhesus Monkeys
JOURNAL OF VIROLOGY, Sept. 2003, p. 10113 10118 Vol. 77, No. 18 0022-538X/03/$08.00 0 DOI: 10.1128/JVI.77.18.10113 10118.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Magnitude
More informationHOST-PATHOGEN CO-EVOLUTION THROUGH HIV-1 WHOLE GENOME ANALYSIS
HOST-PATHOGEN CO-EVOLUTION THROUGH HIV-1 WHOLE GENOME ANALYSIS Somda&a Sinha Indian Institute of Science, Education & Research Mohali, INDIA International Visiting Research Fellow, Peter Wall Institute
More informationstaining and flow cytometry
Detection of influenza virus-specific T cell responses by intracellular by cytokine intracellular staining cytokine staining and flow cytometry Detection of influenza virus-specific T cell responses and
More informationImmunological transitions in response to antigenic mutation during viral infection
International Immunology, Vol. 12, No. 10, pp. 1371 1380 2000 The Japanese Society for Immunology Immunological transitions in response to antigenic mutation during viral infection L. M. Wahl 2, B. Bittner
More informationVirus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef
Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef DAVID T. EVANS 1, DAVID H. O CONNOR 1, PEICHENG JING 1, JOHN L. DZURIS 2, JOHN
More informationIAS 2015 Towards an HIV Cure symposium Vancouver Immune recognition following latency reversal
IAS 2015 Towards an HIV Cure symposium Vancouver Immune recognition following latency reversal Marcus Altfeld Professor of Medicine Outline Immune recognition of HIV-1-infected cells Kinetics of antigen
More informationDecreased EBNA-1-specific CD8 T cells in patients with Epstein Barr virus-associated
Decreased EBNA-1-specific CD8 T cells in patients with Epstein Barr virus-associated nasopharyngeal carcinoma Mark H. Fogg a, Lori J. Wirth b, Marshall Posner b, and Fred Wang a,1 a Department of Medicine,
More informationCurrent Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a Case Study
Note: I have added some clarifying comments to the slides -- please click on Comments under View to see them. Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a
More informationSelection on the Human Immunodeficiency Virus Type 1 Proteome following Primary Infection
JOURNAL OF VIROLOGY, Oct. 2006, p. 9519 9529 Vol. 80, No. 19 0022-538X/06/$08.00 0 doi:10.1128/jvi.00575-06 Copyright 2006, American Society for Microbiology. All Rights Reserved. Selection on the Human
More informationReceived 31 March 2011/Accepted 19 July 2011
JOURNAL OF VIROLOGY, Oct. 2011, p. 10518 10528 Vol. 85, No. 20 0022-538X/11/$12.00 doi:10.1128/jvi.00655-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Fitness Costs and Diversity
More informationNIH Public Access Author Manuscript Nature. Author manuscript; available in PMC 2009 July 1.
NIH Public Access Author Manuscript Published in final edited form as: Nature. 2009 January 1; 457(7225): 87 91. doi:10.1038/nature07469. Immune Control of an SIV Challenge by a T Cell-Based Vaccine in
More informationLow immune activation despite high levels of pathogenic HIV-1 results in long-term asymptomatic disease
Low immune activation despite high levels of pathogenic HIV-1 results in long-term asymptomatic disease Shailesh K. Choudhary 1 *, Nienke Vrisekoop 2 *, Christine A. Jansen 2, Sigrid A. Otto 2, Hanneke
More informationDual Pressure from Antiretroviral Therapy and Cell-Mediated Immune Response on the Human Immunodeficiency Virus Type 1 Protease Gene
JOURNAL OF VIROLOGY, June 2003, p. 6743 6752 Vol. 77, No. 12 0022-538X/03/$08.00 0 DOI: 10.1128/JVI.77.12.6743 6752.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved. Dual Pressure
More informationDevelopment of a Universal T Cell Vaccine. Tomáš Hanke Weatherall Institute of Molecular Medicine University of Oxford United Kingdom
Development of a Universal T Cell Vaccine Tomáš Hanke Weatherall Institute of Molecular Medicine University of Oxford United Kingdom Development of HIV-1 vaccines Induction of cell-mediated responses Immunogens
More informationA VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART
BIOE 301 LECTURE 10 MITALI BANERJEE A VACCINE FOR HIV HIV HAART Visit wikipedia.org and learn the mechanism of action of the five classes of antiretroviral drugs. (1) Reverse transcriptase inhibitors (RTIs)
More informationHow Many Human Immunodeficiency Virus Type 1-Infected Target Cells Can a Cytotoxic T-Lymphocyte Kill?
JOURNAL OF VIROLOGY, Nov. 2005, p. 13579 13586 Vol. 79, No. 21 0022-538X/05/$08.00 0 doi:10.1128/jvi.79.21.13579 13586.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved. How Many
More informationEvidence of HIV-1 Adaptation to HLA- Restricted Immune Responses at a Population Level. Corey Benjamin Moore
Evidence of HIV-1 Adaptation to HLA- Restricted Immune Responses at a Population Level Corey Benjamin Moore This thesis is presented for the degree of Doctor of Philosophy of Murdoch University, 2002 I
More informationThe Immune Epitope Database Analysis Resource: MHC class I peptide binding predictions. Edita Karosiene, Ph.D.
The Immune Epitope Database Analysis Resource: MHC class I peptide binding predictions Edita Karosiene, Ph.D. edita@liai.org IEDB Workshop October 29, 2015 Outline Introduction MHC-I peptide binding prediction
More informationGOVX-B11: A Clade B HIV Vaccine for the Developed World
GeoVax Labs, Inc. 19 Lake Park Drive Suite 3 Atlanta, GA 3 (678) 384-72 GOVX-B11: A Clade B HIV Vaccine for the Developed World Executive summary: GOVX-B11 is a Clade B HIV vaccine targeted for use in
More informationSUPPLEMENTARY INFORMATION
Supplementary Notes 1: accuracy of prediction algorithms for peptide binding affinities to HLA and Mamu alleles For each HLA and Mamu allele we have analyzed the accuracy of four predictive algorithms
More informationHIV-Specific IL-2 + and/or IFN-γ + CD8 + T Cell Reponses during Chronic HIV-1 Infection in Former Blood Donors
BIOMEDICAL AND ENVIRONMENTAL SCIENCES 23, 391-401 (2010) HIV-Specific IL-2 + and/or IFN-γ + CD8 + T Cell Reponses during Chronic HIV-1 Infection in Former Blood Donors YAN-MENG FENG *,±,#,+, YAN-MIN WAN
More informationSupplementary Figure 1. Enhanced detection of CTLA-4 on the surface of HIV-specific
SUPPLEMENTARY FIGURE LEGEND Supplementary Figure 1. Enhanced detection of CTLA-4 on the surface of HIV-specific CD4 + T cells correlates with intracellular CTLA-4 levels. (a) Comparative CTLA-4 levels
More informationRapid Reversion of Sequence Polymorphisms Dominates Early Human Immunodeficiency Virus Type 1 Evolution
REFERENCES CONTENT ALERTS Rapid Reversion of Sequence Polymorphisms Dominates Early Human Immunodeficiency Virus Type 1 Evolution Bin Li, Adrianne D. Gladden, Marcus Altfeld, John M. Kaldor, David A. Cooper,
More informationPrimary Human Immunodeficiency Virus Type 1 (HIV-1) Infection during HIV-1 Gag Vaccination
JOURNAL OF VIROLOGY, Mar. 2008, p. 2784 2791 Vol. 82, No. 6 0022-538X/08/$08.00 0 doi:10.1128/jvi.01720-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. Primary Human Immunodeficiency
More informationNIH Public Access Author Manuscript J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2013 September 01.
NIH Public Access Author Manuscript Published in final edited form as: J Acquir Immune Defic Syndr. 2012 September 1; 61(1): 19 22. doi:10.1097/qai.0b013e318264460f. Evaluation of HIV-1 Ambiguous Nucleotide
More informationEscaich Sonia, COO BIOSANTECH SA.
Escaich Sonia, COO SA. Transactivator of transcription (Tat) of HIV-1 is essential for the viral gene expression and productive infection Tat protein expression is a first step of the virus life cycle
More informationSystematic Identification of Optimal HIV-1 CTL Epitopes
Systematic Identification of Optimal HIV-1 CTL Epitopes Christian Brander and Bruce D. Walker AIDS Research Center, Massachusetts General Hospital, 149 13th Street, Room 5234, Charlestown, MA 02129, USA,
More informationT cell Vaccine Strategies for HIV, the Virus. With a Thousand Faces
JVI Accepts, published online ahead of print on 13 May 2009 J. Virol. doi:10.1128/jvi.00114-09 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationPRACTICE POINTS AIDS Vaccine 2001: Looking to the Future
PRACTICE POINTS AIDS Vaccine 2001: Looking to the Future 1 Ronald T. Mitsuyasu 1 Associate Professor of Medicine, University of California Los Angeles, and Director of the UCLA CARE Center, UCLA Medical
More informationHIV-1 Tat vaccines. Barbara Ensoli, Aurelio Cafaro. Mini Review
Virus Research 82 (2002) 91 101 www.elsevier.com/locate/virusres Mini Review HIV-1 Tat vaccines Barbara Ensoli, Aurelio Cafaro Laboratory of Virology, Retro irus Di ision, Istituto Superiore di Sanita,
More informationHLA-B63 Presents HLA-B57/B58-Restricted Cytotoxic T-Lymphocyte Epitopes and Is Associated with Low Human Immunodeficiency Virus Load
JOURNAL OF VIROLOGY, Aug. 2005, p. 10218 10225 Vol. 79, No. 16 0022-538X/05/$08.00 0 doi:10.1128/jvi.79.16.10218 10225.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved. HLA-B63
More informationI declare that I have no financial conflicts of interest
I declare that I have no financial conflicts of interest Cytotoxic T-Lymphocytes Eliminate Defective HIV Proviruses Without Impacting Infectious Reservoirs R. Brad Jones Assistant Professor The George
More informationSUPPLEMENTARY INFORMATION
` SUPPLEMENTAL FIGURES doi:10.1038/nature10003 Supplemental Figure 1: RhCMV/SIV vectors establish and indefinitely maintain high frequency SIV-specific T cell responses in diverse tissues: The figure shows
More informationThe Role of B Cell Follicles in HIV Replication and Persistence
The Role of B Cell ollicles in HIV Replication and Persistence Elizabeth Connick, M.D. Professor of Medicine Chief, Division of Infectious Diseases University of Arizona July 17, 2016 IAS 2016 Towards
More informationEpitope Specific CD8 + T Cell Responses Predict Spontaneous Control of HIV Replication
Epitope Specific CD8 + T Cell Responses Predict Spontaneous Control of HIV Replication Florencia Pereyra, MD Partners AIDS Research Center Harvard Medical School Boston, MA Background HIV -1 elicits HLA
More informationReceived May 1, 2002; returned to author for revision May 20, 2002; accepted June 3, 2002
Virology 301, 365 373 (2002) doi:10.1006/viro.2002.1598 A Simian Immunodeficiency Virus Nef Peptide Is a Dominant Cytotoxic T Lymphocyte Epitope in Indian-Origin Rhesus Monkeys Expressing the Common MHC
More informationTracking the Culprit: HIV-1 Evolution and Immune Selection Revealed by Single-Genome Amplification
Tracking the Culprit: HIV-1 Evolution and Immune Selection Revealed by Single-Genome Amplification The Harvard community has made this article openly available. Please share how this access benefits you.
More informationCD8 T cells play a critical role in the control of viral infections
HIV-1-specific IFN- IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells Simone C. Zimmerli, Alexandre Harari, Cristina Cellerai, Florence Vallelian, Pierre-Alexandre
More informationHLA-Associated Viral Mutations Are Common in Human Immunodeficiency Virus Type 1 Elite Controllers
JOURNAL OF VIROLOGY, Apr. 2009, p. 3407 3412 Vol. 83, No. 7 0022-538X/09/$08.00 0 doi:10.1128/jvi.02459-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. HLA-Associated Viral Mutations
More informationThe HIV-1 plasma RNA level (VL) measured after acute
Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects Gabriel M. Ortiz*, Melissa Wellons, Jason Brancato,HaT.T.Vo, Rebekah L. Zinn, Daniel E. Clarkson*, Katherine Van
More informationon January 7, 2019 by guest
JOURNAL OF VIROLOGY, Nov. 2000, p. 10489 10497 Vol. 74, No. 22 0022-538X/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. Pathogenic Simian/Human Immunodeficiency Virus
More informationDeveloping Understanding of CMI. Dr Tom Wilkinson Associate Professor of Respiratory Medicine Faculty of Medicine University of Southampton UK
Pre-existing influenza-specific CD4+ T cells correlate with homologous and heterotypic response and disease protection against influenza challenge in humans Do At Risk Groups Rely more on CMI to Viruses?
More informationTemporal effect of HLA-B*57 on viral control during primary HIV-1 infection
Vaidya et al. Retrovirology 2013, 10:139 SHORT REPORT Temporal effect of HLA-B*57 on viral control during primary HIV-1 infection Open Access Sagar A Vaidya 1,2, Hendrik Streeck 1,3,4, Noor Beckwith 1,
More informationMosaic vaccines elicit CD8 + T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys
Mosaic vaccines elicit CD + T lymphocyte responses that fer enhanced immune coverage of diverse HIV strains in monkeys 21 Nature America, Inc. All rights reserved. Sampa Santra 1, Hua-Xin Liao 2, Ruijin
More information